Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD): A Multicenter, Prospective Observational Cohort Study in US Transplant Centers

NCT07607327 is registered in ClinicalTrials.gov with CareDx as lead sponsor.

NCT NCT07607327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07607327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD): A Multicenter, Prospective Observational Cohort Study in US Transplant Centers
Lead sponsor
CareDx
Phase
Observational
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
August 31, 2030
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myelogenous leukemia), cmml, mds (myelodysplastic syndrome)